echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The State Food and Drug Administration approved the marketing of torudibin lafaxine hydrochloride sustained-release tablets

    The State Food and Drug Administration approved the marketing of torudibin lafaxine hydrochloride sustained-release tablets

    • Last Update: 2022-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the State Medical Products Administration approved the marketing
    of the Class 1 innovative drug Torudiven Lafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) declared by Shandong Luye Pharmaceutical Co.
    , Ltd.
    The drug is an innovative drug independently developed by China with independent intellectual property rights, which is suitable for the treatment
    of depression.
     
    The antidepressant effect of torludivenlafaxine hydrochloride may be related to
    the enhancement of 5-HT, NE effects of the central nervous system by inhibiting the reuptake of serotonin (5-HT), norepinephrine (NE).
    The launch of the drug provides more treatment options
    for patients with depression.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.